benign

Terazosin hydrochloride (Hytrin) , a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline.

Dapoxetine (Dapoxetina) is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

Fiduxosin is a selective and potent α1-adrenoceptor antagonist with inhibitory effects on α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, with Ki values of 0.160 nM, 24.9 nM and 0.920 nM, respectively. Fiduxosin can be used for the treatment of benign prostatic hyperplasia.

L-771688 (SNAP 6383) is a novel potent and selective α1A-adrenoceptor antagonist with a Ki value of 0.43±0.02 nM.L-771688 KE is used for the treatment of benign prostatic hyperplasia.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

Taprizosin(UK-338003) is a selective and orally active α1-adrenoceptor antagonist for vasodilatation in the treatment of benign prostatic hyperplasia.

Xinidamine (BRN 0891979) has antitumor activity and can be used to study benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia .Xinidamine inhibits the proliferation of PWR-1E cells with an IC50 of 4 μM.

Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).

Dutasteride (GI 198745) is a 5-alpha-reductase inhibitor that inhibits both type-1 and type2 isoforms of the enzyme and is used to treat benign prostatic hyperplasia.

Phenylethyl isothiocyanate (JC5411) is an HDAC inhibitor. It potentially for the treatment of benign prostatic hypertrophy.

Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH). It treats difficulty urinating, a common symptom of an enlarged prostate, by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, easing urination.

Gisadenafil besylate (UK 369003-26) is a potent and orally active PDE5 inhibitor (IC50=1.23 nM), 100 times more selective for PDE5 than PDE6, for the study of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Gestonorone Capronate  is a progesterone used to treat benign prostatic hyperplasia and endometrial cancer.

Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

Mepartricin, a polyene macrolide, exhibits both antifungal and antiprotozoal activities and is extensively utilized in studies related to benign prostatic hyperplasia.

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor with an IC50 of 4.2 nM for type II 5α-reductase, demonstrating approximately 100-fold higher affinity for type II than type I. Finasteride acetate can be used for research on benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).

Doxazosin (UK 33274) is a long-acting α1-adrenoceptor inhibitor widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms.

L-771688 is an α1A-adrenoceptor antagonist potentially for the treatment of benign prostatic hyperplasia.

ONO-0300302 is a slow tight binding LPA1 antagonist (IC50: 0.16 nM) used to treat Benign Prostatic Hyperplasia. ONO-0300302 inhibits significantly an LPA-induced increase of intraurethral pressure (IUP) in rat (3 mg kg, p.o.) and dog (1 mg kg, p.o.) over

TF-505, a steroid 5α-reductase inhibitor, is used potentially for the treatment of benign prostatic hyperplasia.